Aurobindo Pharma Ltd a 2% share-price drop

AUROPHARMA Aurobindo Pharma’s wholly owned subsidiary Apitoria Pharma received a “Voluntary Action Indicated” (VAI) classification from the USFDA for its Unit-II API manufacturing facility in Gaddapotharam, Telangana, following an inspection from September 7–15, 2026; the agency issued an Establishment Inspection Report (EIR) and closed the inspection under 21 CFR 20.64(d)(3), with no regulatory action planned but corrective measures left to the company. The announcement triggered a nearly 2% share-price decline, snapping a 12-day winning streak, though the stock had been trading near ₹1,200–1,250 in recent sessions. In Q2 FY27 (quarter ended September 30, 2026), the company reported record revenue of ₹10,263 crore (up 24% YoY), operating EBITDA of ₹2,156 crore (up 28% YoY, margin 21.0%), and net profit of ₹1,124 crore (up 33% YoY), with US revenue up 25% to ₹4,555 crore on 10 product launches and 12 final approvals; the board declared an interim dividend of ₹7 per share (700%), with November 11 as the record date and payment by November 20.